Some animal data have raised the possibility that benzodiazepines influence the risk of selected cancers.
With data collected in 1977-1991 in a US hospital-based study, the authors assessed the relation of benzodiazepine use to the risk of 11 cancers : breast (6,056 patients), large bowel (2,203), malignant melanoma (1,457), lung (1,365), endometrium (812), ovary (767), non-Hodgkin's lymphoma (382), testis (314), Hodgkin's disease (299), thyroid (111), and liver (37).
Cases were compared with cancer controls (3,777 patients with other cancers) and noncancer controls (1,919 patients admitted for acute nonmalignant disorders).
Relative risks were estimated for benzodiazepine use at least 4 days a week for at least 1 month, initiated at least 2 years before admission (sustained use) by multiple logistic regression with control for confounding factors.
Results derived with noncancer controls were similar to those derived with cancer controls.
For sustained benzodiazepine use relative to no use, relative risk estimates for all 11 cancers were compatible with 1.0 at the 0.05 level of significance.
The results suggest absence of association between benzodiazepine use and the cancers considered, with the evidence stronger for the cancers with larger numbers of subjects.
The similarity of results derived with cancer and noncancer controls suggests that benzodiazepines do not influence the risk of cancer as a whole.
An J Epidemiol 1995 ; 141 : 1153-60.
Mots-clés Pascal : Diazépam, Chlordiazépoxyde, Tranquillisant, Hypnotique, Anticonvulsivant, Toxicité, Carcinogène, Homme, Epidémiologie, Tumeur maligne, Etats Unis, Amérique du Nord, Amérique, Benzodiazépine dérivé
Mots-clés Pascal anglais : Tranquillizer, Hypnotic, Anticonvulsant, Toxicity, Carcinogen, Human, Epidemiology, Malignant tumor, United States, North America, America, Benzodiazepine derivatives
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0378292
Code Inist : 002B02U10. Création : 01/03/1996.